MNTA's Q2 earnings call should be right around the corner (early to mid August) and could be rather interesting as Management should have some color on the launch and additional discussion regarding Copaxone related hearings, etc.
Based on a scenario based calculation that I put together, I would expect sell-side analyst price targets to fall in the mid-to-upper $30's with an upper band (best case scenario) of $50-60.
Market Data 
Markets 
AI
